Matthias Kretzler presents an infrastructure to study a specific set of kidney rare diseases at Rare Disease Day.
Dr. Kretzler presented an introduction to the framework infrastructure used to study a specific set of kidney rare diseases at the Rare Disease Day conference last month.
Watch his presentation here.
The Kidney Precision Medicine Project (KPMP) and the Nephrotic Syndrome Study Network (NEPTUNE) recently published a landmark study in the journal JCI Insight. This work highlights the relevance of a new and emerging technology in exposing underlying mechanisms involved in kidney disease progression.
University of Michigan Medical School Office of Research recently published a video featuring the UMMS Central Biorepository (CBR). Director Victoria Blanc, Ph.D., walks through the process of accessing and storing biospecimens and MiKTMC’s Matthias Kretzler, MD speaks about how the samples from our cohort study networks across the world are managed using the CBR.
Funding from NIH, U-M, and NephCure International to Support Research of Major Cause of Rare Kidney Diseases
The National Center for Advancing Translational Sciences (NCATS) and the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) recently awarded a third five-year cycle of funding to support the Nephrotic Syndrome Study Network (NEPTUNE), a member of the Rare Diseases Clinical Research Network (RDCRN).
The Nephrotic Syndrome Research Network is revolutionizing the field of glomerular kidney disease research
Now in its ninth year, the benefits of laying the groundwork for the Nephrotic Syndrome Research Network (NEPTUNE) are beginning to come into fruition. As NephCure CEO Josh Tarnoff notes, “It’s hard to overstate NEPTUNE’s impact on our understanding of FSGS and related syndromes. For example, one of the data sets presented by NEPTUNE at ASN Kidney Week 2016 provided the much-needed evidence correlating proteinuria levels to survival. This no doubt assisted the FDA to evolve their guidelines to accept proteinuria…
Patients with Chronic Kidney Disease (CKD) may benefit from a new collaboration between U-M and AstraZeneca, who have partnered to develop a new therapeutic strategy for treatment. The partners will jointly conduct chemistry and drug discovery research with the aim of...
As the world gets smaller, Michigan Medicine’s place in it gets bigger. That’s thanks to partnerships like the one which recently took nearly 80 faculty abroad to meet with research collaborators in China.
We recently collaborated with Emily Somers, Ph.D., Sc.M., an associate professor of internal medicine (rheumatology), environmental health sciences and obstetrics and gynecology at U-M and a member of the U-M Institute for Healthcare Policy and Innovation, to help...
Pre-competitive consortium will work to identify new treatment targets for renal disease